

April 5, 2011

Astellas Assesses the Impact of the Eastern Japan Earthquake (3rd Notice)

Tokyo, April 5, 2011 - [Astellas Pharma Inc.](#) (“Astellas”, TSE: 4503) expresses its deepest sympathy for those who have lost their lives and been displaced by the Eastern Japan Earthquake, which devastated the region on Friday, March 11, 2011. Astellas looks forward to a quick recovery from this natural calamity and offers its support in the relief efforts. Astellas reports on the most recent conditions of its facilities which Astellas has confirmed until today in the wake of the Eastern Japan Earthquake below.

1. Nishine Plant* (Astellas Pharma Tech Co., Ltd. (former Astellas Tokai Co., Ltd), Hachimantai-shi, Iwate prefecture, “Nishine Plant”)

In the 2nd notice released on March 23, Astellas announced that the shipments of some products began at the Nishine Plant. Because Astellas has confirmed that its manufacturing facilities will function normally, it has decided to resume full operations of both manufacturing and shipments of products from tomorrow.

*Nishine Plant is the formulating and packaging plant to produce the products including Harnal, Lipitor and Perdipine.

2. Impact Upon Earnings

Astellas is currently assessing the impact of the earthquake upon its earnings and will quickly disclose pertinent information should it discover that its earnings are likely to be significantly impacted.

Except for the above there is no update from the 2nd notice released on March 23.

About Astellas Pharma Inc.

Astellas Pharma Inc., located in Tokyo, Japan, is a global pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. Astellas has approximately 16,000 employees worldwide. The organization is committed to becoming a global category leader in urology, immunology and infectious diseases, neuroscience, DM complications and metabolic diseases and oncology. For more information on Astellas Pharma Inc., please visit our website at <http://www.astellas.com/en>.

#####

Contacts for inquiries or additional information
--

Astellas Pharma Inc.(Japan)

Corporate Communications

Tel: +81-3-3244-3201 Fax: +81-3-5201-7473

http://www.astellas.com/en
